Voyager Therapeutics, Inc. (VYGR)
| Market Cap | 210.87M +10.1% |
| Revenue (ttm) | 36.49M -45.5% |
| Net Income | -116.64M |
| EPS | -1.98 |
| Shares Out | 60.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 275,189 |
| Open | 3.550 |
| Previous Close | 3.550 |
| Day's Range | 3.485 - 3.585 |
| 52-Week Range | 2.830 - 5.550 |
| Beta | 1.25 |
| Analysts | Strong Buy |
| Price Target | 14.89 (+326.65%) |
| Earnings Date | Aug 5, 2026 |
About VYGR
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small mo... [Read more]
Financial Performance
In 2025, Voyager Therapeutics's revenue was $40.37 million, a decrease of -49.53% compared to the previous year's $80.00 million. Losses were -$119.72 million, 84.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price target is $14.89, which is an increase of 326.65% from the latest price.
News
Voyager Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The summit featured updates on tau-targeting therapies for Alzheimer's, including gene therapy and antibody approaches, with key data readouts expected in 2026 and beyond. Advancements in delivery platforms and strategic partnerships position the company for significant milestones and clinical progress.
UNLOCKING SPACE: Elon Musk is BREAKING RECORDS for orbital launches
Voyager Technologies Chairman and CEO Dylan Taylor joins ‘Mornings with Maria' to discuss SpaceX's record-breaking IPO, the rise of the space economy and Voyager's first year as a public company.
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced ...
Voyager Therapeutics Transcript: AGM 2026
The meeting covered director elections, executive compensation, auditor ratification, and an amendment to increase authorized shares. All proposals passed by majority or plurality, with final results to be filed in Form 8-K.
Voyager Therapeutics announces FDA clearance for VY1706 IND application
Voyager Therapeutics (VYGR) announced that the FDA has cleared its investigational new drug, or IND, application for VY1706, the company’s investigational gene therapy targeting intracellular and extr...
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease
- Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses ...
Voyager Therapeutics presents GLP for toxicology data for VY1706
Voyager Therapeutics (VYGR) presented three-month good laboratory practice, or GLP, toxicology data for VY1706, the Company’s investigational tau silencing gene therapy for Alzheimer’s disease, or AD,...
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mas...
Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)
Reports Q1 revenue $2.59M, consensus $8.79M. “As the ‘Year of Tau’ for Alzheimer’s disease continues to unfold, Voyager looks forward to third-party data in mid-2026 that have the potential to…
Voyager Reports First Quarter 2026 Financial and Operating Results
- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended ...
Voyager Therapeutics Quarterly report: Q1 2026
Voyager Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Voyager Therapeutics Earnings release: Q1 2026
Voyager Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Voyager Therapeutics management to meet with Oppenheimer
Meeting to be held on April 28 hosted by Oppenheimer.
Voyager Therapeutics Proxy statement: Proxy filing
Voyager Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Voyager Therapeutics Proxy statement: Proxy filing
Voyager Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease
- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs -
Voyager Therapeutics management to meet with Oppenheimer
Meeting to be held on April 13 hosted by Oppenheimer.
Voyager Therapeutics Proxy statement: Proxy filing
Voyager Therapeutics filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Voyager Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
2026 is positioned as a pivotal year with major tau-targeted programs advancing, including gene therapy and antibody assets, and the first clinical use of BBB-penetrant capsids. Key data readouts and expanded partnerships are expected to drive progress in neurodegenerative disease innovation.
Voyager Therapeutics reports Q4 EPS (46c), consensus (51c)
Reports Q4 revenue $15.34M, consensus $10.49M. “Building on our pipeline progress in 2025, Voyager expects 2026 to be a pivotal year defined by three pillars of value creation: data on…
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies...
Voyager Therapeutics Earnings release: Q4 2025
Voyager Therapeutics released its Q4 2025 earnings on March 9, 2026, summarizing the period's financial results.
Voyager Therapeutics Annual report: Q4 2025
Voyager Therapeutics has published its Q4 2025 annual report on March 9, 2026.
Voyager Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Three strategic pillars—tau-targeting, gene therapy, and NeuroShuttle—drive innovation, with two gene therapies entering the clinic and strong financial runway. Tau PET imaging is central to clinical development, and partnerships are key for advancing large-scale Alzheimer's trials.
Voyager to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced ...